13.71
price down icon0.29%   -0.04
pre-market  プレマーケット:  13.93   0.22   +1.60%
loading
前日終値:
$13.75
開ける:
$13.78
24時間の取引高:
1.39M
Relative Volume:
0.80
時価総額:
$4.37B
収益:
$3.05B
当期純損益:
$181.32M
株価収益率:
36.69
EPS:
0.3737
ネットキャッシュフロー:
$225.64M
1週間 パフォーマンス:
+6.28%
1か月 パフォーマンス:
+3.86%
6か月 パフォーマンス:
+15.50%
1年 パフォーマンス:
+79.92%
1日の値動き範囲:
Value
$13.70
$13.96
1週間の範囲:
Value
$12.49
$13.96
52週間の値動き範囲:
Value
$7.53
$15.42

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
名前
Amneal Pharmaceuticals Inc
Name
セクター
Healthcare (1100)
Name
電話
908-947-3120
Name
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
職員
5,210
Name
Twitter
@amnealpharma
Name
次回の収益日
2026-05-01
Name
最新のSEC提出書
Name
AMRX's Discussions on Twitter

Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AMRX icon
AMRX
Amneal Pharmaceuticals Inc
13.71 4.39B 3.05B 181.32M 225.64M 0.3737
TAK icon
TAK
Takeda Pharmaceutical Co Adr
15.74 49.29B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
8.89 40.34B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.26 39.81B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
78.82 33.30B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
544.69 23.34B 3.17B 1.29B 1.01B 27.09

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-17 開始されました UBS Buy
2025-12-09 開始されました Barclays Overweight
2025-06-06 開始されました Goldman Buy
2025-02-24 アップグレード JP Morgan Neutral → Overweight
2024-09-06 アップグレード JP Morgan Underweight → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2021-03-08 アップグレード Goldman Sell → Buy
2020-12-14 アップグレード Barclays Equal Weight → Overweight
2020-12-14 アップグレード Guggenheim Neutral → Buy
2020-07-27 開始されました Goldman Sell
2020-05-12 アップグレード Guggenheim Sell → Neutral
2019-12-12 ダウングレード Raymond James Outperform → Mkt Perform
2019-11-12 ダウングレード JP Morgan Neutral → Underweight
2019-11-07 ダウングレード SVB Leerink Outperform → Mkt Perform
2019-07-22 アップグレード SVB Leerink Mkt Perform → Outperform
2019-07-11 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-07-08 アップグレード Piper Jaffray Neutral → Overweight
2019-06-11 開始されました Barclays Equal Weight
2019-05-21 アップグレード Raymond James Mkt Perform → Strong Buy
2019-03-20 開始されました SunTrust Buy
2019-03-08 ダウングレード SVB Leerink Outperform → Mkt Perform
2018-12-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2018-10-16 ダウングレード SunTrust Buy → Hold
2018-08-13 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-07-23 開始されました Morgan Stanley Overweight
2018-06-22 開始されました B. Riley FBR, Inc. Buy
すべてを表示

Amneal Pharmaceuticals Inc (AMRX) 最新ニュース

pulisher
Jun 08, 2026

Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN

Jun 08, 2026
pulisher
Jun 08, 2026

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution - Pharmacy Practice News

Jun 08, 2026
pulisher
Jun 07, 2026

Why Amneal (AMRX) stock is trading up today - MSN

Jun 07, 2026
pulisher
Jun 06, 2026

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data - Sahm

Jun 06, 2026
pulisher
Jun 06, 2026

How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations - Yahoo Finance

Jun 06, 2026
pulisher
Jun 05, 2026

Amneal reports interim data on Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal reports interim data for Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution - The Globe and Mail

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal reports interim data on Parkinson’s drug CREXONT - Investing.com UK

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal Pharmaceuticals Reports Positive Interim Data from Phase 4 ELEVATE-PD Study Demonstrating Benefits of CREXONT in Parkinson's Disease Patients - Quiver Quantitative

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease - The Manila Times

Jun 05, 2026
pulisher
Jun 05, 2026

Parkinson’s study: CREXONT adds over 3 hours of daily 'Good On' time - Stock Titan

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo

Jun 05, 2026
pulisher
Jun 05, 2026

AMRX News | AMNEAL PHARMACEUTICALS INC (NASDAQ:AMRX) - ChartMill

Jun 05, 2026
pulisher
Jun 05, 2026

Amneal Stock Up on FDA Approval of Romidepsin Injection for Lymphoma PatientsNews and Statistics - IndexBox

Jun 05, 2026
pulisher
Jun 04, 2026

Why Amneal (AMRX) Stock Is Trading Up Today - Yahoo Finance UK

Jun 04, 2026
pulisher
Jun 04, 2026

Amneal Pharmaceuticals Inc (AMRX) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus

Jun 04, 2026
pulisher
Jun 04, 2026

Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution - Proactive financial news

Jun 04, 2026
pulisher
Jun 04, 2026

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.

Jun 04, 2026
pulisher
Jun 04, 2026

Amneal Pharmaceuticals Advances After Securing FDA Clearance for Cancer Treatment (AMRX) - Yahoo Finance

Jun 04, 2026
pulisher
Jun 04, 2026

Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com - Investing.com Nigeria

Jun 04, 2026
pulisher
Jun 04, 2026

Amneal Pharmaceuticals stock gains on FDA approval for cancer drug - Investing.com

Jun 04, 2026
pulisher
Jun 01, 2026

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? - Yahoo! Finance Canada

Jun 01, 2026
pulisher
Jun 01, 2026

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times

Jun 01, 2026
pulisher
Jun 01, 2026

Amneal CEO to present at Goldman Sachs 2026 Global Healthcare Conference in June - Pluang

Jun 01, 2026
pulisher
May 29, 2026

Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains - Sahm

May 29, 2026
pulisher
May 27, 2026

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

May 27, 2026
pulisher
May 26, 2026

Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now? - The Globe and Mail

May 26, 2026
pulisher
May 24, 2026

Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN

May 24, 2026
pulisher
May 23, 2026

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - MSN

May 23, 2026
pulisher
May 23, 2026

Is Amneal Pharmaceuticals (AMRX) Poised for Growth After a Strong Q1 2026 - Kavout

May 23, 2026
pulisher
May 20, 2026

A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- G - GuruFocus

May 20, 2026
pulisher
May 20, 2026

A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- GF Value $7.57 vs Price $12.21 - GuruFocus

May 20, 2026
pulisher
May 20, 2026

Stronger Q1 Profitability And Reaffirmed Outlook Could Be A Game Changer For Amneal (AMRX) - simplywall.st

May 20, 2026
pulisher
May 20, 2026

Amneal Pharmaceuticals Is Maintained at Overweight by Barclays - Moomoo

May 20, 2026
pulisher
May 19, 2026

Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks

May 19, 2026

Amneal Pharmaceuticals Inc (AMRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
RGC RGC
$21.39
price up icon 7.00%
RDY RDY
$13.23
price down icon 0.08%
$23.68
price up icon 0.21%
$163.12
price up icon 0.00%
$15.93
price up icon 0.31%
$544.69
price down icon 0.94%
大文字化:     |  ボリューム (24 時間):